Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021.
Switzerland
cellular therapies
demographics
hematopoietic cell transplantation
long term care
outcome
relative risk
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
06 Dec 2023
06 Dec 2023
Historique:
revised:
26
10
2023
received:
28
08
2023
accepted:
15
11
2023
medline:
7
12
2023
pubmed:
7
12
2023
entrez:
7
12
2023
Statut:
aheadofprint
Résumé
The Swiss Blood Stem Cell Transplantation and Cellular Therapy Group (SBST) leads a mandatory national registry for all hematopoietic stem cell transplants (HCT) and cellular therapies. After 25 years, information was available for 11,226 patients receiving an HCT (4031 allogeneic and 7195 autologous), including 925 pediatric patients. We compared patient characteristics and outcome by quinquennia 1997-2001, 2002-2006, 2007-2011, 2012-2016, and 2017-2021. There were numerous changes over time. Allogeneic transplant recipients became older (median age 33.7 vs. 54.3) and had more frequently unrelated donors and reduced intensity conditioning in later quinquennia. Similarly, age increased for recipients of autologous HCT (median 48.3 vs. 59.9). We did not see a significant drop in transplant activity during the SARS-CoV-2 pandemic. Analysis of outcome showed overall survival (relative risk (RR) of death 0.664 (0.529-0.832) and progression free survival (RR 0.708 (0.577-0.870) being improved over time comparing the latest to the first quinquennium adjusting for risk factors. Non-relapse mortality decreased in recipients of allogeneic HCT (RR: 0.371 (0.270-0.509)) over time but relapse risks did not. Outcome of autologous HCT improved as well across quinquennia, this improvement was mainly due to decreased relapse risks (RR 0.681 (0.597-0.777)), possibly related to maintenance treatment or rescue treatment for relapse mainly in myeloma patients. Cellular therapies other than allogeneic or autologous HCT, particularly chimeric antigen receptor T-cells (CAR-T) treatment have started to increase after 2019, year of approval of the first commercial CAR-T product in Switzerland. Data on chimeric antigen receptor T-cell treatment are too early for comparative analyses. Detailed analyses of changes over time are presented. This study includes all HCTs, and cellular therapies, data useful for quality assurance programs, health care cost estimation and benchmarking. Between 50% and 60% of patients are long-term survivors after both types of HCT, indicating growing populations of surviving patients requiring long-term care.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Gratwohl A, Gmur J, Chapuis B, et al. 12 years' experience in bone marrow transplantation in leukemic patients in Switzerland. Schweiz Med Wochenschr. 1986;116:1477-1478. https://pubmed.ncbi.nlm.nih.gov/3538380/
Leibundgut K, Hirt A, Luthy AR, Wagner HP, Tobler A. Single institution experience with mobilization, harvesting and reinfusion of peripheral blood stem cells in children with a solid tumor or leukemia. Pediatr Hematol Oncol. 1994;11(2):215-221. https://doi.org/10.3109/08880019409141660
Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813-1826. https://doi.org/10.1056/NEJMra052638
Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998:087-092. https://doi.org/10.1016/s0140-6736(98)03030-x
Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007;357(15):1472-1475. https://doi.org/10.1056/NEJMp078166
Gratwohl A, Pasquini MC, Aljurf M, et al. Worldwide Network for Blood and Marrow Transplantation (WBMT). One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015;2(3):e91-e100. https://doi.org/10.1016/S2352-3026(15)00028-9
Fehr T, Hübel K, de Rougemont O, et al. Successful induction of specific immunological tolerance by combined kidney and hematopoietic stem cell transplantation in HLA-identical siblings. Front Immunol. 2022;13:796456. https://doi.org/10.3389/fimmu.2022.796456
Tyndall A Successes and failures of stem cell transplantation in autoimmune diseases. Hematol Am Soc Hematol Educ Program. 2011;2011(1):280-284. https://doi.org/10.1182/asheducation-2011.1.280
Ruder J, Docampo MJ, Rex J, et al. Dynamics of T cell repertoire renewal following autologous hematopoietic stem cell transplantation in multiple sclerosis. Sci Transl Med. 2022;14(669). Epub 2022 Nov 2. https://doi.org/10.1126/scitranslmed.abq1693
Passweg JR, Baldomero H, Ansari M, et al. Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss blood stem cell transplantation working group for blood and marrow transplantation registry 1997-2016. Swiss Med Wkly. 2018;148:w14589. https://doi.org/10.4414/smw.2018.14589
Passweg J, Baldomero H, Chapuis B, Leibundgut K, Schanz U. Gratwohl A haematopoietic stem cell transplantation in Switzerland. Report from the Swiss transplant working group blood and marrow transplantation (STABMT) registry 1997-2003. Swiss Med Wkly. 2006;136(3-4):50-58. https://doi.org/10.4414/smw.2018.14589
Passweg J, Baldomero H, Stern M, et al. Hematopoietic stem cell transplantation in Switzerland: a comprehensive quality control report on centre effect. Swiss Med Wkly. 2010;140(23-24):326-334. https://doi.org/10.4414/smw.2010.12978
Snowden JA, Sánchez-Ortega I, Corbacioglu S, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transpl. 2022;57(8):1217-1239. https://doi.org/10.1038/s41409-022-01691
Saccardi R, Putter H, Eikema DJ, et al. Benchmarking of survival outcomes following haematopoietic stem cell transplantation (HSCT): an update of the ongoing project of the European society for blood and marrow transplantation (EBMT) and joint accreditation committee of ISCT and EBMT (JACIE). Bone Marrow Transpl. 2023;58(6):659-666. https://doi.org/10.1038/s41409-023-01924-6
Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706. https://doi.org/10.1002/(sici)1097-0258(19990330)18:6<695:aid-sim60>3.0.co;2-o
Klein JP, Wu TJ. Handbook of Statistics: Advances in Survival Analysis Discretizing a Continuous Covariate in Survival Studies. Elseiver; 2004. https://doi.org/10.1016/S0169-7161(03)23002-9
Passweg JR, Baldomero H, Bader P, et al. Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2017;52(2):191-196. https://doi.org/10.1038/bmt.2016.258
Gratwohl A, Stern M, Brand R, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115(20):4715-4726. https://doi.org/10.1002/cncr.24531
Passweg JR, Baldomero H, Chabannon C, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2021;56(7):1651-1664. https://doi.org/10.1038/s41409-021-01227-8
Passweg JR, Baldomero H, Chabannon C, et al. Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2022;57(5):742-752. https://doi.org/10.1038/s41409-022-01604-x
Passweg JR, Baldomero H, Ciceri F, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transpl. 2023;58(6):647-658. https://doi.org/10.1038/s41409-023-01943-3
El Sawy M, Storer BE, Pulsipher MA, et al. Multi-centre validation of the prognostic value of the haematopoietic cell transplantation-specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. Br J Haematol. 2015;170(4):574-583. https://doi.org/10.1111/bjh.13476
Artz AS. Biologic vs physiologic age in the transplant candidate. Hematol Am Soc Hematol Educ Program. 2016;2016(1):99-105. https://doi.org/10.1182/asheducation-2016.1.99
Muffly L, Pasquini MC, Martens M, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130(9):1156-1164. https://doi.org/10.1182/blood-2017-03-772368
Hahn T, McCarthy PL, Jr, Hassebroek A, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol. 2013;31(19):2437-2449. https://doi.org/10.1200/JCO.2012.46.6193
Munshi PN, Hamadani M, Kumar A, et al. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transpl. 2021;56(12):2911-2921. https://doi.org/10.1038/s41409-021-01288-9